India, April 17 -- image credit- shutterstock

VENUSREM, BSE: 526953), a Panchkula-based pharmaceutical company specialising in critical care injectables, has announced that its investigational productVRP-034has been grantedQualified Infectious Disease Product (QIDP)designation by theUnited States Food and Drug Administration (US FDA)for the treatment of bloodstream infections caused by polymyxin B (PMB)-susceptible strains in adults.

Developed byVenus Medicine Research Centre (VMRC), the R&D division of Venus Remedies, VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate, uniquely developed to address the nephrotoxic effects associated with conventional polymyxin B therapy.

The QIDP designation, granted ...